Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under MBX Biosciences, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is Steven Hoerter, President and Chief Executive Officer (Form 8-K filed 2026-07-13). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Orbimed Advisors LLC (filed 2026-08-10).
Who is behind it
MBX Biosciences, Inc.: incorporated in Delaware; business address in Carmel, Indiana; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- Peter Kent Hawryluk: Executive Officer, Director (Form D, 2022-11-18)
- Richard DiMarchi: Executive Officer, Director (Form D, 2022-11-18)
- Ora Pescovitz: Director (Form D, 2022-11-18)
- James M. Cornelius: Director (Form D, 2022-11-18)
- Carl Gordon: Director (Form D, 2022-11-18)
- Patrick Heron: Director (Form D, 2022-11-18)
- Edward Mathers: Director (Form D, 2022-11-18)
- Tiba Aynechi: Director (Form D, 2022-11-18)
- Richard Bartram: Executive Officer (Form D, 2022-11-18)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Deep Track Capital, LP | 3.64% |
| Schedule 13D/A, 2026-08-10 | Orbimed Advisors LLC | 6.4% |
| Schedule 13D/A, 2026-08-10 | Frazier Life Sciences Public Fund, L.P. | 11.7% |
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 5.5% |
| Schedule 13G/A, 2026-07-08 | Wellington Management Group LLP | 10.5% |
| Schedule 13G/A, 2026-07-08 | Fmr LLC | 11.2% |
| Schedule 13G, 2026-06-24 | Paradigm Biocapital Advisors LP | 5.2% |
| Schedule 13G, 2026-05-06 | Fmr LLC | 6.2% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-13 | Steven Hoerter | President and Chief Executive Officer | appointed | 2026-07-13 |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2022-11-18 | $46.68M | $115.18M |
Latest IPO step: MBX Biosciences, Inc. filed its final IPO prospectus, ticker MBX (424B4, 2025-09-25).
IPO filings: 424B4, 2025-09-25, S-1, 2025-09-22, S-1/A, 2024-09-09, S-1/A, 2024-08-30, S-1, 2024-08-23; ticker MBX on Nasdaq Global Select Market.
Related pages
Leadership changes5%+ holdersIPO filings
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/mbx-biosciencesLast updated 2026-10-18
Primary record: Schedule 13D/A, 2026-08-10 · Form D, 2022-11-18 · Form 8-K, 2026-07-13 · 424B4, 2025-09-25
Who owns MBX Biosciences, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/mbx-biosciences